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Biochemical, clinical and genetic evidence indicates that
in neuropsychiatric disorders the alteration of mem-
brane phospholipids metabolism can play a protogenetic
role associated with that of the proportional balance of
polyunsaturated fatty acids.
Various PUFA have been experimented with as thera-
peutic and helpful means of protection in the treatment
of neuropsychiatric pathologies. Among these, treat-
ments with pure ethyl-eicosapentaenoic acid (EPA) in
double blind clinical studies compared with the placebo
have been proved to be more effective. Its biosynthesis
starts from alpha-linoleic acid and the activity of the
delta-6 desaturated enzyme.
Ethyl EPA modifies the activity of PLA2, the alteration
of which is accompanied by structural changes in neuro-
nal membranes, observed in depressed patients as well
as those with Alzheimer’s disease. It is enormously
important as both precursor to active eicosanoids, which
is as capable of competing with AA for the incorpora-
tion of the membrane as it is for the substrate according
to the so called “fatty acid paradox” for the production
of the DHA organism when this is necessary. Such EPA
activity, which is crucial for the transmission of inter-
neuronal signals, it interferes of phosphatidyl inositol
bisphosphate regulation, linked to the activity of the
alpha subunit of the G protein. The hydrolysis derivates
of PIP2 they are the second messenger associated with
different neurotransmissional systems and metabolic
process. EPA interferes in the process, inhibiting the
protein kinase-C AMPc- dependent (PKC). In vitro inhi-
bit the activity of PKC of the protein kinase II Ca2+/cal-
modulina dependent and inhibit the activation, induced
by 5HT, of the protein kinase activated by mithogen
(MAPK).The proposed mechanism of pure ethyl EPA as
the calcium-antagonist, blocking Ca2+ channels, is con-
firmed in cardiovascular studies. Blocking calcium chan-
nels could reduce the hyperactive signal transduction
process.
Finally, EPA inhibits the production of pro-inflamma-
tory cytokines that they are the main responsible for the
appearance of the so called “Sickness behaviour
syndrome”. Such data is important in recognising that
the integrity and functionality of biomolecules is closely
connected to the functionality of pure eicosanoid acids
(EPA), from both the perspective of nutritional habits
and that of therapy for neuropsychiatric illnesses.
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